drugset / Trial / NCT03509688

The Curative Effect of Entecavir Combined Resveratrol on HBV patients-a Multi-center, Random, Open Clinical Trial

NCT03509688

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to use entecavir combined with other drug such as resveratrol and thymosin to treat patients with hepatitis B, which may provide a novel therapy target hepatitis B.

Timeline

Start
2014-11
Primary completion
2017-12
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Resveratrol Small molecule 1000 mg
Subject Thymalfasin Peptide
Background Entecavir Small molecule 0.5 mg

Indications